СПОСОБ ЭКСПРЕСС-АНАЛИЗА IN VITRO ЧУВСТВИТЕЛЬНОСТИ ГРАМОТРИЦАТЕЛЬНЫХ БАКТЕРИЙ К АНТИБИОТИКАМ И ЕГО ПРИМЕНЕНИЕ ДЛЯ КОНТРОЛЯ ЭФФЕКТИВНОСТИ АНТИБАКТЕРИАЛЬНОЙ ТЕРАПИИ
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU NAUCHNO-PROIZVODSTVENNAYA FIRMA "ROKHAT" (OOO NPF "ROKHAT")
发明人:
NIYAZMATOV, Agzamdzhan Akhtamovich,НИЯЗМАТОВ, Агзамджан Ахтамович,YAKOVLEVA, Alla Nikolaevna,ЯКОВЛЕВА, Алла Николаевна,RYABIKOVA, Maria Alexeevna,РЯБИКОВА, Мария Алексеевна
申请号：
RURU2014/000074
公开号：
WO2015/115926A1
申请日:
2014.01.31
申请国别(地区):
WO
年份:
2015
代理人:
摘要：
The group of inventions relates to medicine, microbiology and laboratory diagnostics, and provides for accuracy and simplicity of rapid in-vitro analysis of Gram-negative bacteria sensitivity to antibiotics, and for the effectiveness of said antibiotics in a patient using a diagnostic preparation "MAP-Endotox spp.". The rapid analysis of bacteria sensitivity includes the following stages: a) selecting a sample of biological fluid (BF), b) determining a minimum concentration (MC) of a general endotoxin (LPS) using a method of activated particles (MAP) by adding, to a concavity in a tablet, 100 microliters (1%) of a buffer solution, 100 microliters of the biological fluid (BF) and 20 microliters of a diagnostic preparation, and titrating same using a double-dilution method, c) incubating the mixture for 5 minutes at 37°С, d) adding, to the 100 microliters of biological fluid, 100 microliters of an antibiotic to be tested or of antibiotics to be tested in an amount of 1/5000 of the one-time estimated dose thereof per 1 milliliter of biological fluid and 20 microliters of diagnostic preparation, incubating the mixture produced during stage c for 30 minutes, comparing the results of the reactions from stages b and c, and determining the sensitivity to the antibiotic on the basis of a 2-3 fold increase of the LPS in the mixture relative to the minimum concentration (MC) in stage b. Monitoring the effectiveness of antibacterial therapy before and after the first administration of the antibiotic includes determining the level of LPS in the biological fluid sample directly from the source of the infection, in the blood, urine, cerebrospinal fluid, bile or in a supernatant of a diluted sample of biological fluid, in the sputum, exudate or pus. The therapy is considered to be effective when the LPS is increased by 2 or more times from the initial level.Le groupe dinventions se rapporte au domaine de la médecine, de la microbiologie, des diagnostics en laboratoire et offre une
